[Value of chemotherapy in curative therapy of head and neck therapy]

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

ESMO open·2025

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

ESMO open·2023

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

ESMO open·2022

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

ESMO open·2022

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2021

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

ESMO open·2021

[Preventive approaches in phoniatrics and musicians' medicine-voice physiology and vocal health curriculum content during the training of vocal students].

HNO·2026

Implantation of a transcutaneous, bone-anchored, piezoelectric bone conduction hearing aid on the squama temporalis.

HNO·2026

[Special tumor entities : New results at the 2026 ASCO Annual Meeting].

HNO·2026

[Support needs of people with intellectual disabilities after hearing aid provision].

HNO·2026

[Surgical trials in head and neck cancer at the 2026 ASCO Annual Meeting].

HNO·2026

The new Mainz Audiometric Test for Children aged 3-7 years (MATCH) in noise : Design, normalization, and validation.

HNO·2026

[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

Recenti progressi in medicina·2026

Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway.

Journal of biochemical and molecular toxicology·2026

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

Future oncology (London, England)·2026

[Impact of anesthesia type on results of carotid endarterectomy: analytical review of randomized clinical trials].

Khirurgiia·2026

Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma.

Journal of medical imaging and radiation oncology·2026

Postoperative Management of Direct Oral Anticoagulants After Elective Spine Surgery: When Can These Drugs be Safely Resumed?

Clinical spine surgery·2026

Related Experiment Videos

[Value of chemotherapy in curative therapy of head and neck therapy]

Related Concept Videos

Sex-specific efficacy and safety outcomes in patients with resectable stage III non-small-cell lung cancer (NSCLC) undergoing neoadjuvant therapies: a pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.

Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.

Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.

Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.

A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.

Second-line therapy improves overall survival in primary refractory non-small cell lung cancer (NSCLC) patients.

[Preventive approaches in phoniatrics and musicians' medicine-voice physiology and vocal health curriculum content during the training of vocal students].

Implantation of a transcutaneous, bone-anchored, piezoelectric bone conduction hearing aid on the squama temporalis.

[Special tumor entities : New results at the 2026 ASCO Annual Meeting].

[Support needs of people with intellectual disabilities after hearing aid provision].

[Surgical trials in head and neck cancer at the 2026 ASCO Annual Meeting].

The new Mainz Audiometric Test for Children aged 3-7 years (MATCH) in noise : Design, normalization, and validation.

[Sacituzumab govitecan in a patient with early bone recurrence of triple-negative breast cancer refractory to first-line chemotherapy.]

Quercetin Attenuates Cisplatin-Induced Nephrotoxicity While Enhancing Antitumor Efficacy in Gastric Cancer via Cell Type-Specific Modulation of the ERK1/2 Pathway.

Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective.

[Impact of anesthesia type on results of carotid endarterectomy: analytical review of randomized clinical trials].

Stereotactic Ablative Body Radiotherapy Versus Microwave Ablation for the Treatment of Early-Stage Hepatocellular Carcinoma.

Postoperative Management of Direct Oral Anticoagulants After Elective Spine Surgery: When Can These Drugs be Safely Resumed?

Related Experiment Videos

[Value of chemotherapy in curative therapy of head and neck therapy]

Related Concept Videos

Related Articles